Overview

Price chart · mood · technical indicators

KG

KING PHARMACEUTICALS INCstock Financial Services

Insurance Brokers

$9.7570.45%Current Market Mood:Strong Bearish

Market Mood

Price Range (1Y)

$8.07$36.80

Current: $9.75

Market Comparison

vs Financial Services Sector & Insurance Brokers Industry

-70.45%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio1.11

EPS (TTM)$8.570.0% YoY

Profit margin137.2%FINANCIAL SERVICES

Market cap$87.3MMicro cap

Valuation

Forward P/E: —
PEG ratio: —
P/B: 0.69
P/S (TTM): 2.56
EV/EBITDA: 0.94

Profitability & growth

ROE (TTM): 74.6%
Operating margin: -28.7%
Revenue growth YoY: 737.0%
Dividend yield: —
Beta: —

Last earnings

Nov 6, 2025 · Estimate $0.00 · Reported $-0.65

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

26 articles · sorted by date

Page 1 of 2 · 26 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Kestrel Group, Ltd.

Company profile

Kestrel Group Ltd engages in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers. The company is headquartered in Hamilton, Bermuda.

Classification

Sector: Financial Services
Industry: Insurance - Reinsurance
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 11 BERMUDIANA ROAD, HAMILTON, BERMUDA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$87.3M

Shares outstanding$9.2M

52W high$36.80

52W low$8.07

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

KG

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

Frank D’Amelio, CFO-in-Residence, on Setting Priorities in Challenging Times

Alumnus Establishes Pharmapreneurship Award in Honor of Dean Eddington

Former Biglaw Partner Fails To Understand Seriousness Of His Misconduct

How's Senator Joe Manchin Tied to the EpiPen Scandal?

Pfizer Unit Settles Skelaxin Pay-For-Delay Class Action Lawsuit

$345 Million Settlement Proposed in EpiPen Lawsuits

Pfizer antes up $345M to settle long-running EpiPen antitrust claims as Viatris case moves ahead

Pfizer Agrees to Pay $345M to Settle EpiPen Price Hike Case

Tribunal maintains Lexon’s £1.2m fine for breaking competition law

Epistaxis Market Factor Analysis: Report Includes Value Chain

Lupin gets US health regulator nod to market hypothyroidism tablets

Allergan sues Pfizer over legal fees tied to opioid marketing

U.S. investment adviser gets prison for insider trading on Pfizer-King deal

US: Jury convicts ex-law firm partner of insider trading on Pfizer-King merger

FDA Reviews CorVue SPECT Pharmacologic Stress Agent

Tenn. Skelaxin Indirect Purchaser Class Action Settlement

$2M Skelaxin Class Action Settlement Reached with Indirect Purchasers

Pfizer rolling out painkiller designed to stop abuse

Pfizer Unit Extends Tender Offer To Buy King Pharma To January 28

Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.

About Kestrel Group, Ltd.

Classification

Company profile

KG

Market Comparison

KG Market Analysis

Overview

KG

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

Frank D’Amelio, CFO-in-Residence, on Setting Priorities in Challenging Times

Alumnus Establishes Pharmapreneurship Award in Honor of Dean Eddington

Former Biglaw Partner Fails To Understand Seriousness Of His Misconduct

How's Senator Joe Manchin Tied to the EpiPen Scandal?

Pfizer Unit Settles Skelaxin Pay-For-Delay Class Action Lawsuit

$345 Million Settlement Proposed in EpiPen Lawsuits

Pfizer antes up $345M to settle long-running EpiPen antitrust claims as Viatris case moves ahead

Pfizer Agrees to Pay $345M to Settle EpiPen Price Hike Case

Tribunal maintains Lexon’s £1.2m fine for breaking competition law

Epistaxis Market Factor Analysis: Report Includes Value Chain

Lupin gets US health regulator nod to market hypothyroidism tablets

Allergan sues Pfizer over legal fees tied to opioid marketing

U.S. investment adviser gets prison for insider trading on Pfizer-King deal

US: Jury convicts ex-law firm partner of insider trading on Pfizer-King merger

FDA Reviews CorVue SPECT Pharmacologic Stress Agent

Tenn. Skelaxin Indirect Purchaser Class Action Settlement

$2M Skelaxin Class Action Settlement Reached with Indirect Purchasers

Pfizer rolling out painkiller designed to stop abuse

Pfizer Unit Extends Tender Offer To Buy King Pharma To January 28

Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.

About Kestrel Group, Ltd.

Classification

Company profile

KG

Market Comparison